Short Interest in BioTime, Inc. (BTX) Expands By 3.9%

BioTime, Inc. (NYSEAMERICAN:BTX) was the recipient of a significant growth in short interest during the month of September. As of September 14th, there was short interest totalling 13,666,548 shares, a growth of 3.9% from the August 31st total of 13,153,727 shares. Based on an average daily volume of 505,083 shares, the short-interest ratio is currently 27.1 days. Currently, 10.9% of the shares of the stock are short sold.

Several large investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. increased its holdings in shares of BioTime by 20.9% during the first quarter. Schwab Charles Investment Management Inc. now owns 173,856 shares of the biotechnology company’s stock worth $468,000 after buying an additional 30,056 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of BioTime by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 744,554 shares of the biotechnology company’s stock worth $1,534,000 after buying an additional 33,350 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of BioTime by 5.2% during the first quarter. Northern Trust Corp now owns 966,448 shares of the biotechnology company’s stock worth $2,600,000 after buying an additional 47,957 shares in the last quarter.

NYSEAMERICAN BTX opened at $2.37 on Thursday. BioTime has a fifty-two week low of $1.98 and a fifty-two week high of $3.16.

BioTime (NYSEAMERICAN:BTX) last released its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.03. BioTime had a return on equity of 30.68% and a net margin of 828.55%. The firm had revenue of $2.55 million during the quarter, compared to analysts’ expectations of $0.33 million.

Separately, Zacks Investment Research cut BioTime from a “buy” rating to a “hold” rating in a research note on Tuesday, July 24th.

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Further Reading: What is the Dow Jones Industrial Average (DJIA)?

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply